Circadian clocks and breast cancer

Breast Cancer Research

Volumn 18, Issue 1, 2016, Pages

  Blakeman, Victoria ^a   Williams, Jack L ^a   Meng, Qing Jun ^a   Streuli, Charles H ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PER1 PROTEIN; PER2 PROTEIN; TRANSCRIPTION FACTOR ARNTL; TRANSCRIPTION FACTOR CLOCK;

APOPTOSIS; BMAL1 GENE; BREAST CANCER; CANCER RISK; CELL CYCLE; CELL METABOLISM; CIRCADIAN RHYTHM; CLOCK GENE; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; LIGHT EXPOSURE; METASTASIS; NONHUMAN; PER1 GENE; PER2 GENE; REVIEW; SHIFT WORKER; SINGLE NUCLEOTIDE POLYMORPHISM; SUPRACHIASMATIC NUCLEUS; ANIMAL; ANTIBODY SPECIFICITY; BREAST; BREAST NEOPLASMS; CELL TRANSFORMATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BREAST; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CIRCADIAN CLOCKS; CIRCADIAN RHYTHM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; ORGAN SPECIFICITY; SUPRACHIASMATIC NUCLEUS;

EID: 84984940180     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-016-0743-z     Document Type: Review

References (84)

1. Chen S-T, et al. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005;26:1241-6.
2. Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer J Int Cancer. 2015;136:E359-86.
3. Stevens RG. Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiol Camb Mass. 2005;16:254-8.
4. Gery S, Koeffler HP. Circadian rhythms and cancer. Cell Cycle Georget Tex. 2010;9:1097-103.
5. Hastings MH, Reddy AB, Maywood ES. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci. 2003;4:649-61.
6. Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol. 2010;72:517-49.
7. Cadenas C, et al. Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle Georget Tex. 2014;13:3282-91.
8. Filipski E, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 2002;94:690-7.
9. Hamilton T. Influence of environmental light and melatonin upon mammary tumour induction. Br J Surg. 1969;56:764-6.
10. Reppert SM, Weaver DR. Molecular analysis of mammalian circadian rhythms. Annu Rev Physiol. 2001;63:647-76.
11. Abrahamson EE, Moore RY. Suprachiasmatic nucleus in the mouse: retinal innervation, intrinsic organization and efferent projections. Brain Res. 2001;916:172-91.
12. Welsh DK, Logothetis DE, Meister M, Reppert SM. Individual neurons dissociated from rat suprachiasmatic nucleus express independently phased circadian firing rhythms. Neuron. 1995;14:697-706.
13. Reiter RJ, Tan DX, Korkmaz A, Rosales-Corral SA. Melatonin and stable circadian rhythms optimize maternal, placental and fetal physiology. Hum Reprod Update. 2014;20:293-307.
14. Reiter RJ, Gultekin F, Manchester LC, Tan D-X. Light pollution, melatonin suppression and cancer growth. J Pineal Res. 2006;40:357-8.
15. Pando MP, Morse D, Cermakian N, Sassone-Corsi P. Phenotypic rescue of a peripheral clock genetic defect via SCN hierarchical dominance. Cell. 2002;110:107-17.
16. Pittendrigh CS. Circadian systems. I. The driving oscillation and its assay in Drosophila pseudoobscura. Proc Natl Acad Sci U S A. 1967;58:1762-7.
17. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002;418:935-41.
18. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 2003;3:350-61.
19. Landgraf D, Wang LL, Diemer T, Welsh DK. NPAS2 compensates for loss of CLOCK in peripheral circadian oscillators. PLoS Genet. 2016;12:e1005882.
20. DeBruyne JP, Weaver DR, Reppert SM. CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock. Nat Neurosci. 2007;10:543-5.
21. Gachon F, Olela FF, Schaad O, Descombes P, Schibler U. The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 2006;4:25-36.
22. Sahar S, Sassone-Corsi P. The epigenetic language of circadian clocks. Handb Exp Pharmacol. 2013;(217):29-44.
23. Preitner N, et al. The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell. 2002;110:251-60.
24. Reddy AB, Wong GKY, O'Neill J, Maywood ES, Hastings MH. Circadian clocks: neural and peripheral pacemakers that impact upon the cell division cycle. Mutat Res. 2005;574:76-91.
25. Firestein R, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One. 2008;3:e2020.
26. Yi YW, et al. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells. Oncotarget. 2013;4:984-94.
27. Unsal-Kaçmaz K, Mullen TE, Kaufmann WK, Sancar A. Coupling of human circadian and cell cycles by the timeless protein. Mol Cell Biol. 2005;25:3109-16.
28. Engelen E, et al. Mammalian TIMELESS is involved in period determination and DNA damage-dependent phase advancing of the circadian clock. PLoS One. 2013;8:e56623.
29. Muschler J, Streuli CH. Cell-matrix interactions in mammary gland development and breast cancer. Cold Spring Harb Perspect Biol. 2010;2:a003202.
30. Yoo S-H, et al. PERIOD2::LUCIFERASE real-time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues. Proc Natl Acad Sci U S A. 2004;101:5339-46.
31. Metz RP, Qu X, Laffin B, Earnest D, Porter WW. Circadian clock and cell cycle gene expression in mouse mammary epithelial cells and in the developing mouse mammary gland. Dev Dyn Off Publ Am Assoc Anat. 2006;235:263-71.
32. Casey TM, et al. Tissue-specific changes in molecular clocks during the transition from pregnancy to lactation in mice. Biol Reprod. 2014;90:127.
33. McConnell JC, et al. Increased peri-ductal collagen micro-organization may contribute to raised mammographic density. Breast Cancer Res. 2016;18:5.
34. Sherratt MJ, McConnell J, Streuli CH. Raised mammographic density: causative mechanisms and biological consequences. Breast Cancer Res. 2016;18(1):45.
35. Lin S-T, et al. Nuclear envelope protein MAN1 regulates clock through BMAL1. eLife. 2014;3:e02981.
36. Hoffman AE, et al. CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses. Cancer Res. 2010;70:1459-68.
37. Malik A, Kondratov RV, Jamasbi RJ, Geusz ME. Circadian clock genes are essential for normal adult neurogenesis, differentiation, and fate determination. PLoS One. 2015;10:e0139655.
38. Méndez-Ferrer S, Chow A, Merad M, Frenette PS. Circadian rhythms influence hematopoietic stem cells. Curr Opin Hematol. 2009;16:235-42.
39. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002;111:41-50.
40. Hua H, et al. Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci. 2006;97:589-96.
41. Gery S, et al. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006;22:375-82.
42. Kelleher FC, Rao A, Maguire A. Circadian molecular clocks and cancer. Cancer Lett. 2014;342:9-18.
43. Shostak A, et al. MYC/MIZ1-dependent gene repression inversely coordinates the circadian clock with cell cycle and proliferation. Nat Commun. 2016;7:11807.
44. Matsuo T, et al. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003;302:255-9.
45. Asher G, et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell. 2008;134:317-28.
46. Xiao B, et al. Structure of mammalian AMPK and its regulation by ADP. Nature. 2011;472:230-3.
47. Lamia KA, et al. AMPK regulates the circadian clock by cryptochrome phosphorylation and degradation. Science. 2009;326:437-40.
48. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403:795-800.
49. Vaziri H, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001;107:149-59.
50. Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science. 2009;324:654-7.
51. Nakahata Y, et al. The NAD + -dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell. 2008;134:329-40.
52. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 2003;144:5179-83.
53. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011;25:1895-908.
54. Um JH, et al. Activation of 5"-AMP-activated kinase with diabetes drug metformin induces casein kinase Iepsilon (CKIepsilon)-dependent degradation of clock protein mPer2. J Biol Chem. 2007;282:20794-8.
55. Zhu Y, et al. Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treat. 2008;107:421-5.
56. Rossetti S, Corlazzoli F, Gregorski A, Azmi NHA, Sacchi N. Identification of an estrogen-regulated circadian mechanism necessary for breast acinar morphogenesis. Cell Cycle Georget Tex. 2012;11:3691-700.
57. Akhtar N, Streuli CH. An integrin-ILK-microtubule network orients cell polarity and lumen formation in glandular epithelium. Nat Cell Biol. 2013;15:17-27.
58. Gery S, Virk RK, Chumakov K, Yu A, Koeffler HP. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene. 2007;26:7916-20.
59. Green KA, Carroll JS. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer. 2007;7:713-22.
60. Teboul M, Gréchez-Cassiau A, Guillaumond F, Delaunay F. How nuclear receptors tell time. J Appl Physiol Bethesda Md. 2009;1985(107):1965-71.
61. Jiang W, et al. The circadian clock gene Bmal1 acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway. Cancer Lett. 2016;371:314-25.
62. Climent J, et al. Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:3770-8.
63. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. 2001;93:1557-62.
64. Hansen J. Increased breast cancer risk among women who work predominantly at night. Epidemiol Camb Mass. 2001;12:74-7.
65. Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer Oxf Engl. 2005;1990(41):2023-32.
66. Schernhammer ES, Kroenke CH, Laden F, Hankinson SE. Night work and risk of breast cancer. Epidemiol Camb Mass. 2006;17:108-11.
67. Stevens RG. Light-at-night, circadian disruption and breast cancer: assessment of existing evidence. Int J Epidemiol. 2009;38:963-70.
68. Haus EL, Smolensky MH. Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Med Rev. 2013;17:273-84.
69. Richter K, et al. Recommendations for the prevention of breast cancer in shift workers. EPMA J. 2011;2:351-6.
70. Menegaux F, et al. Night work and breast cancer: a population-based case-control study in France (the CECILE study). Int J Cancer. 2013;132:924-31.
71. Hurley S, et al. Light at night and breast cancer risk among California teachers. Epidemiol Camb Mass. 2014;25:697-706.
72. Van Dycke KCG, et al. Chronically Alternating Light Cycles Increase Breast Cancer Risk in Mice. Curr Biol CB. 2015;25:1932-7.
73. Schernhammer ES, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst. 2001;93:1563-8.
74. Brainard GC, Richardson BA, King TS, Reiter RJ. The influence of different light spectra on the suppression of pineal melatonin content in the Syrian hamster. Brain Res. 1984;294:333-9.
75. Blask DE, Dauchy RT, Sauer LA, Krause JA, Brainard GC. Growth and fatty acid metabolism of human breast cancer (MCF-7) xenografts in nude rats: impact of constant light-induced nocturnal melatonin suppression. Breast Cancer Res Treat. 2003;79:313-20.
76. Hill SM, et al. Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer. 2015;22:R183-204.
77. Dauchy RT, et al. Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. Cancer Res. 2014;74:4099-110.
78. Bracci M, et al. Rotating-shift nurses after a day off: peripheral clock gene expression, urinary melatonin, and serum 17-β-estradiol levels. Scand J Work Environ Health. 2014;40:295-304.
79. Kochan DZ, et al. Circadian disruption-induced microRNAome deregulation in rat mammary gland tissues. Oncoscience. 2015;2:428-42.
80. Kochan DZ, et al. Circadian-disruption-induced gene expression changes in rodent mammary tissues. Oncoscience. 2016;3:58-70.
81. Gautherie M, Gros C. Circadian rhythm alteration of skin temperature in breast cancer. Chronobiologia. 1977;4:1-17.
82. Mormont MC, Lévi F. Circadian-system alterations during cancer processes: a review. Int J Cancer J Int Cancer. 1997;70:241-7.
83. Schubauer-Berigan MK, et al. Breast cancer incidence in a cohort of U.S. flight attendants. Am J Ind Med. 2015;58:252-66.
84. Stevens RG, Brainard GC, Blask DE, Lockley SW, Motta ME. Breast cancer and circadian disruption from electric lighting in the modern world. CA Cancer J Clin. 2014;64:207-18.